Human wharton’s jelly mesenchymal stem cell secretome shows additive cytotoxic effect in combination with chemotherapeutic agent doxorubicin on k562 leukemia cells without making cancer cells resistant to the medicine
- At: 2014 FIP Congress in Bangkok (Thailand)
- Type: Poster
- By: HENDIJANI, Fatemeh (Isfahan University of Medical Sciences, Pharmaceutical Biotechnology, Esfahan, Iran)
- Co-author(s): Haghjooy Javanmard, Shaghayegh (Isfahan University of Medical Sciences, Esfahan, Iran)
Sadeghi Ali-Abadi, Hojjat (Isfahan University of Medical Sciences, Esfahan, Iran)
Setting: Pharmaceutical Biotechnology Department
Background: Mesenchymal stem cell (MSC) therapy is progressively moving toward clinical use. Clinical trials on MSC use in diverse medical conditions are now carrying out. MSCs display anticancer effects in several studies. So their effect on cancer cell lines should be investigated more carefully... The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.